Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 1, 2012, Pages 24-32

  Xue, Hui Yi ^a   Wong, Ho Lun ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Breast cancer; Chemoresistance; Megalin; Non viral delivery; siRNA; Targeted delivery

Indexed keywords

CLUSTERIN; MEGALIN; NANOCARRIER; PACLITAXEL; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; CELL SUBPOPULATION; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FREEZE DRYING; PARTICLE SIZE; PH; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOLIPOPROTEINS E; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPIDS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2; NANOPARTICLES; PACLITAXEL; POLYETHYLENEIMINE; RNA, SMALL INTERFERING;

EID: 84861096858     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.02.005     Document Type: Article

References (35)

1. M.P. Shekhar Drug resistance: challenges to effective therapy Curr. Cancer Drug Targets 11 2011 613 623
2. G.I. Solyanik Multifactorial nature of tumor drug resistance Exp. Oncol. 32 2010 181 185
3. L. O'Driscoll, and M. Clynes Biomarkers and multiple drug resistance in breast cancer Curr. Cancer Drug Targets 6 2006 365 384
4. J.T. Garrett, and C.L. Arteaga Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications Cancer Biol. Ther. 11 2011 793 800
5. H.L. Wong, A.M. Rauth, R. Bendayan, and X.Y. Wu Simultaneous delivery of doxorubicin and GG918 (Elacridar) using polymer-lipid hybrid nanoparticles (PLN) and evaluation of strategies for multidrug-resistance reversal in human breast cancer cells J. Control. Release 116 2006 275 284
6. H.L. Wong, A.M. Rauth, R. Bendayan, and X.Y. Wu Evaluation of the in vivo efficacy, toxicity and lymphatic drainage of loco-regional administered polymer-lipid hybrid nanoparticles (PLN) loaded with doxorubicin in a murine solid tumor model Eur. J. Pharm. Biopharm. 65 2007 300 308
7. C. Di Cresce, and J. Koropatnick Antisense treatment in human prostate cancer and melanoma Curr. Cancer Drug Targets 10 2010 555 565
8. O. Heidenreich Targeting oncogenes with siRNAs Methods Mol. Biol. 487 2009 221 242
9. A. Fire, S. Xu, M. Montgomery, S. Kostas, S. Driver, and C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
10. H.L. Wong, Z. Shen, Z. Lu, M.G. Wientjes, and J.L-S. Au Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures Mol. Pharmaceut. 8 2011 833 840
11. D. Reischl, and A. Zimmer Drug delivery of siRNA therapeutics: potentials and limits of nanosystems Nanomedicine 5 2009 8 20
12. A. Judge, and I. MacLachlan Overcoming the innate immune response to small interfering RNA Hum. Gene Ther. 19 2008 111 124
13. O. Snove Jr., and J.J. Rossi Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi Genome Biol. 7 2006 231
14. M.J. Rowling, C.M. Kemmis, D.A. Taffany, and J. Welsh Megalin-mediated endocytosis of vitamin D binding protein correlates with 25- hydroxycholecalciferol actions in human mammary cells J. Nutr. 136 2006 2754 2759
15. T.M. Chlon, D.A. Taffany, J. Welsh, and M.J. Rowling Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin D-binding protein in human mammary cells J. Nutr. 138 2008 1323 1328
16. M.O. Pedersen, P.B. Hansen, S.L. Nielsen, and M. Penkowa Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas Leukemia Lymphoma 51 2010 314 328
17. H.Y. Xue, and H.L. Wong Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted and safer siRNA therapy of prostate cancer in an all-in-one manner ACS Nano 2011 10.1021/nn201659z
18. H.Y. Xue, and H.L. Wong Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization Biomaterials 32 2011 2662 2672
19. T.M. Goppert, and R.H. Muller Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns J. Drug Target 13 2005 179 187
20. H.R. Kim, K. Andrieux, S. Gil, M. Taverna, H. Chacun, D. Desmaële, F. Taran, D. Georgin, and P. Couvreur Translocation of poly(ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: Role of apolipoproteins in receptor-mediated endocytosis Biomacromolecules 8 2007 793 799
21. L. Flanagan, L. Whyte, N. Chatterjee, and M. Tenniswood Effects of clusterin over-expression on metastatic progression and therapy in breast cancer BMC Cancer 10 2010 107
22. R. Frazzi, B. Casali, M. Iori, D. Nicoli, C. Mammi, and F. Merli Increase in clusterin forms part of the stress response in Hodgkin's lymphoma Int. J. Oncol. 38 2011 677 684
23. F.P. Girard, J. Byrne, M. Downes, D. Fanning, F. Desgrandchamps, J.M. Fitzpatrick, and R.W. Watson Detecting soluble clusterin in in-vitro and in-vivo models of prostate cancer Neoplasma 57 2010 488 493
24. M. Redondo, T. Tellez, M.J. Roldan, A. Serrano, M. Garcia-Aranda, M.E. Gleave, M.L. Hortas, and M. Morell Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity Breast Cancer Res. 9 2007 R86
25. A. Zoubeidi, K. Chi, and M. Gleave Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer Clin. Cancer Res. 16 2010 1088 1093
26. R.D. Sowery, B.A. Hadaschik, A.I. So, A. Zoubeidi, L. Fazli, A. Hurtado-Coll, and M.E. Gleave Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy BJU Int. 102 2008 389 397
27. L. Flanagan, L. Whyte, N. Chatterjee, and M. Tenniswood Effects of clusterin over-expression on metastatic progression and therapy in breast cancer BMC Cancer 2010 10 2010 107 10.1186/1471-2407-10-107
28. H.M. Ghonaim, S. Li, and I.S. Blagbrough N1, N12-diacyl spermines: SAR studies on non-viral lipopolyamine vectors for plasmid DNA and siRNA formulation Pharm. Res. 27 2010 17 29
29. R. Paridaens, L. Biganzoli, P. Bruning, J.G.M. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, A. Awada, J. Wildiers, and M. Piccart Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over J. Clin. Oncol. 18 2000 724 733
30. E. Ring Taxanes in the treatment of early breast cancer Cancer Treat. Rev. 31 2005 618 627
31. S.K. Holt, D.M. Karyadi, E.M. Kwon, J.L. Stanford, P.S. Nelson, and E.A. Ostrander Association of megalin genetic polymorphisms with prostate cancer risk and prognosis Clin. Cancer Res. 14 2008 3823 3831
32. J.L. Stanford, K.G. Wicklund, B. McKnight, J.R. Daling, and M.K. Brawer Vasectomy and risk of prostate cancer Cancer Epidemiol. Biomarkers Prev. 8 1999 881 886
33. H. Ammar, and J.L. Closset Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway J. Biol. Chem. 283 2008 12851 12861
34. J. Liu, H.L. Wong, J. Moselhy, B. Bowen, X.Y. Wu, and M. Johnston. Targeting colloidal particulates to thoracic lymph nodes Lung Cancer 51 2006 377 386
35. A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K.N. Jayaprakash, M. Jayaraman, K.G. Rajeev, W.L. Cantley, J.R. Dorkin, J.S. Butler, L. Qin, T. Racie, A. Sprague, E. Fava, A. Zeigerer, M.J. Hope, M. Zerial, D.W. Sah, K. Fitzgerald, M.A. Tracy, M. Manoharan, V. Koteliansky, A. Fougerolles, and M.A. Maier Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms Mol. Ther. 18 2010 1357 1364